Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E. Rosenberg, Robert Dreicer, Sandy Srinivas et al.|The Lancet|2016Cited by 3.7k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Toni K. Choueiri et al.|The Lancet|2020Cited by 1.8k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trialThomas Powles, Alain Ravaud, Ignacio Durán et al.|The Lancet|2017Cited by 1.4k
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Daniel Castellano et al.|The Lancet Oncology|2017Cited by 1.3k
ctDNA guiding adjuvant immunotherapy in urothelial carcinomaThomas Powles, Sanjeev Mariathasan, Zoe J. Assaf et al.|Nature|2021Cited by 603